Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
AstraZeneca has agreed to settle a class action lawsuit accusing the company of scheming to block generic competition to its antipsychotic drug.
read more
Key to the deal is STC-004, a phase 2 ready oral Nav1.8 inhibitor being studied for the treatment of pain
read more
The company has dosed the first patient in the 10,000-person portion of its ongoing phase 2b clinical trial evaluating its oral pill COVID vaccine candidate.
read more
According to TurtleTree, this marks the first time any regulatory body has approved the bioactive milk protein produced through precision fermentation.
read more
The company is focused on treatments for patients suffering from major depressive disorder, Alzheimer’s disease, schizophrenia and other synaptopathies.
read more
Key to the $470M deal is Vigil’s VG-3927, an oral small molecule TREM2 agonist.
read more
The new platform is based on an optimized design of experiments, a statistical approach to process and reaction condition optimization.
read more
The Series C funding will be used to advance the company’s novel oral p300/CBP inhibitor, inobrodib, for the treatment of multiple myeloma.
read more
RJx-01 is an orally administered proprietary combination drug that has the potential to meaningfully address sarcopenia.
read more
Barentz has entered exclusive discussions to acquire 100% equity of Fengli Group, a specialty chemicals distributor for pharma excipients and APIs in China.
read more
The once-daily pill is a first-in-class combination of aroxybutynin and atomoxetine.
read more
The FDA’s Office of Prescription Drug Promotion has flagged promotional communications from Mayne regarding its Nextstellis combined hormonal contraceptives.
read more
UnitedHealth Group CEO Andrew Witty has stepped down as CEO and the company, citing “personal reasons.”
read more
Madrigal, looking to expand Rezdiffra into patient populations with compensated MASH cirrhosis, has now announced two-year biomarker results from this group.
read more
The makers of Nature Made vitamins announced the grand opening of a new manufacturing and research & development facility in New Albany, Ohio.
read more